Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.

Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4832-7. doi: 10.1073/pnas.0711372105.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.

Shen L, Siliciano RF.

J Allergy Clin Immunol. 2008 Jul;122(1):22-8. doi: 10.1016/j.jaci.2008.05.033. Review.

PMID:
18602567
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
6.
7.
8.

[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].

Llibre JM, Martínez-Picado J.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:17-22. Review. Spanish.

PMID:
19572421
9.

HIV integrase as a target for antiretroviral therapy.

Hazuda DJ.

Curr Opin HIV AIDS. 2012 Sep;7(5):383-9. doi: 10.1097/COH.0b013e3283567309. Review.

PMID:
22871634
10.

Emerging drug targets for antiretroviral therapy.

Reeves JD, Piefer AJ.

Drugs. 2005;65(13):1747-66. Review.

PMID:
16114975
11.

Novel targets for antiretroviral therapy: clinical progress to date.

Dau B, Holodniy M.

Drugs. 2009;69(1):31-50. doi: 10.2165/00003495-200969010-00003. Review.

PMID:
19192935
12.

HIV type 1 integrase inhibitors: from basic research to clinical implications.

Jegede O, Babu J, Di Santo R, McColl DJ, Weber J, Quiñones-Mateu M.

AIDS Rev. 2008 Jul-Sep;10(3):172-89. Review.

PMID:
18820719
13.

Raltegravir: the first HIV type 1 integrase inhibitor.

Hicks C, Gulick RM.

Clin Infect Dis. 2009 Apr 1;48(7):931-9. doi: 10.1086/597290. Review.

PMID:
19231980
14.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

PMID:
23687291
15.
16.

Promising anti-HIV compounds in preclinical or early clinical development.

Litterst C.

Adv Exp Med Biol. 1996;394:397-404. Review. No abstract available.

PMID:
8815704

Supplemental Content

Support Center